Facebook Pixel Code
About Sickkids
About SickKids

Manuel Carcao, MD

The Hospital for Sick Children

Research Institute
Senior Associate Scientist
Child Health Evaluative Sciences

University of Toronto
Associate Professor

Phone: 416-813-5367
Fax: 416-813-5327

Brief Biography

Dr. Carcao is a Clinician Investigator in the Division of Haematology/Oncology (Department of Paediatrics), Senior Associate Scientist in the Child Health Evaluative Sciences program at SickKids and Associate Professor of Paediatrics at the University of Toronto. He is also a member of the Hemostasis program in Haematology.

Dr. Carcao received his medical degree in 1990 and a Masters of Science degree in Clinical Epidemiology in 2007 from the University of Toronto. He joined the division as a faculty member in 1999 following completion of haematology/oncology and hemostasis fellowships (1995-1999). 

Dr Carcao has served in many organizational and administrative capacities in the field of bleeding disorders. These include:

  • President; Association of Hemophilia Clinic Directors of Canada (AHCDC; 2006 to 2008)
  • Chair; Inhibitor Subcommittee of the AHCDC (2002-06; 2013-2017)
  • Chair; Canadian Paediatric Thrombosis and Haemostasis Network (2016-present)
  • Chair; Canadian Haemophilia Society Peer Review Committee (2016-present)
  • Chair; INPH (International Network of Paediatric Hemophilia). (2017-present)
  • Co-Chair; FVIII, FIX and Rare Inherited Bleeding Disorders Subcommittee of the ISTH

    He is on the editorial board of several well-known journals. He has been an invited lecturer on many occasions, and is the author of over 120 peer-reviewed papers and textbook chapters.

Research Interests

  • Prevention of bleeding in haemophilia
  • Inhibitor development in haemophilia
  • Immune thrombocytopenia purpura
  • Clinical trials
  • Hereditary Spherocytosis and other red cell membrane disorders
  • Medical management of vascular tumors and malformations

Research Activities

Dr. Carcao’s research interests are in the study of congenital bleeding disorders (haemophilia, Von Willebrand disease and rare inherited coagulation and platelet disorders) and in particular the study of inter-patient disease variability with respect to inhibitor development, prophylaxis needs and pharmacokinetics. Dr. Carcao also has a substantial clinical and research interest in childhood immune thrombocytopenia, hereditary spherocytosis and the medical management of vascular tumours and malformations.


Al-Battat S, Rand ML, Bouskill V, Lau W, Blanchette VS, Kahr WHA, Rivard GE, Carcao M. Glanzmannthrombasthenia platelets compete with transfused platelets reducing the haemostatic impact of transfused platelets. Br J Haematol, 2017 May 3. [Epub ahead of print]

Carcao M, Avila L, Leissinger C, Blanchette V, Aledort L on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators. An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia. Haemophilia 2017 Apr 24. [Epub ahead of print]

Carcao M, Avila L, Leissinger C, Blanchette V, Aledort L on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators. An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia. Haemophilia 2017 Apr 21. [Epub ahead of print]

Carcao M, Kearney S, Santagostino E, Oyesiku JO, Young NL, Meunier J, Hoxer CS, Zhang C, Blanchette VS. Insight in health-related quality of life of young children with haemophilia B treated with a long-acting nonacog beta pegol recombinant factor IX. Haemophilia 2017 May; 23(3):e222-e224 Mar 30.

Labarque V, Perinparajah V, Bouskill V, Stain AM, Wakefield C, Manuel M, Blanchette VS, Carcao MD.Factor VIII and Von Willebrand factor levels in 277 unselected carriers of hemophilia A. Am J Hematol 2017 Jun; 92(6):E94-E96.

Sholzberg  M, Floros G, Schneiderman JE, Kahr W, Rand ML, Pluthero F, Hossain T, Mahamad S, Nisenbaum, R, Zhang, C, Whitney, K, O’Neill, NE Teitel J, Carcao M. Effect of Moderate Intensity Exercise on Hemostatic Capacity in Adults with Hemophilia A and B: Pilot Study. Haemophilia 2017 Mar; 23(2): e162-165.

Carcao M, Fukutake K, Inbal A, Kerlin B, Lassila R, Oldenburg J, Garly M-L, Nugent D. Developing the first recombinant Factor XIII for congenital Factor XIII deficiency: clinical challenges and successes.Seminars in Thrombosis and Haemostasis 2017 Feb;43(1):59-68.

Bouskill V, Hilliard P, Stephens S, Whitney K, Zhang C, Carcao M. An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys with Haemophilia. Haemophilia 2016. Sep;22(5):e383-9.

Carcao M, Zak M, Abdul Karim F, Hanabusa H, Kearney S, Lu MY, Persson P, Rangarajan S, Santagostino E on behalf of the paradigm™5 investigators. Nonacog beta pegol (N9-GP) in previously treated children with hemophilia B: results from an international, open-label, phase 3 trial. J Thromb Haemost 2016 Aug; 14(8):1521-1529.

Kumar R, Bouskill V, Kahr W, Craik, Pluthero F, Schneiderman JE, Clark D, Whitney K, Zhang C, Rand ML, Carcao MD. Impact of Exercise on Hemostasis in Boys with Hemophilia A (HA) and B (HB): Principal Findings of the SickKids Hemophilia Exercise Study. Thromb Haemost 2016 Jun 2;115(6):1120-8.

Kumar R, Dunn A, Carcao M. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Seminars in Thrombosis and Haemostasis 2016 Feb; 42(1):18-29.

Carcao M, Srivastava A. FVIII/FIX Prophylaxis for Severe Hemophilia. Semin Hematol 2016 Jan; 53(1):3-9.

Carcao M, Re W, Ewenstein B. The Role of Previously Untreated Patient Studies in Understanding the Development of FVIII Inhibitors. Haemophilia 2016 Jan; 22(1):22-31.